Equities analysts expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to post $2.26 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The highest sales estimate is $3.28 million and the lowest is $1.50 million. Tetraphase Pharmaceuticals reported sales of $1.09 million during the same quarter last year, which indicates a positive year over year growth rate of 107.3%. The firm is expected to report its next earnings report on Wednesday, March 14th.
On average, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $2.26 million for the current financial year, with estimates ranging from $8.60 million to $10.41 million. For the next year, analysts anticipate that the company will post sales of $6.81 million per share, with estimates ranging from $4.00 million to $13.39 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Tetraphase Pharmaceuticals.
TTPH has been the topic of a number of recent research reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $8.00 target price on shares of Tetraphase Pharmaceuticals in a report on Wednesday, February 14th. HC Wainwright boosted their target price on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, November 6th. Zacks Investment Research lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. BidaskClub lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Finally, ValuEngine lowered Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $10.39.
In other Tetraphase Pharmaceuticals news, Director L Patrick Gage acquired 3,880 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The shares were purchased at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the acquisition, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jacques Dumas sold 8,750 shares of the company’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the transaction, the insider now directly owns 8,750 shares in the company, valued at approximately $54,425. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.
A number of hedge funds have recently made changes to their positions in TTPH. Schwab Charles Investment Management Inc. grew its holdings in Tetraphase Pharmaceuticals by 0.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock worth $925,000 after acquiring an additional 874 shares during the period. Alliancebernstein L.P. grew its holdings in Tetraphase Pharmaceuticals by 6.9% during the second quarter. Alliancebernstein L.P. now owns 59,200 shares of the biopharmaceutical company’s stock worth $422,000 after acquiring an additional 3,800 shares during the period. Ameriprise Financial Inc. acquired a new position in Tetraphase Pharmaceuticals during the second quarter worth $162,000. Northern Trust Corp grew its holdings in Tetraphase Pharmaceuticals by 4.8% during the second quarter. Northern Trust Corp now owns 886,765 shares of the biopharmaceutical company’s stock worth $6,323,000 after acquiring an additional 40,668 shares during the period. Finally, California Public Employees Retirement System grew its holdings in Tetraphase Pharmaceuticals by 2.0% during the second quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock worth $1,727,000 after acquiring an additional 4,800 shares during the period. 56.34% of the stock is currently owned by hedge funds and other institutional investors.
Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $2.08 on Wednesday. The stock has a market capitalization of $107.32, a P/E ratio of -0.72 and a beta of 2.28. Tetraphase Pharmaceuticals has a twelve month low of $2.05 and a twelve month high of $9.93.
WARNING: “$2.26 Million in Sales Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.thestockobserver.com/2018/02/21/2-26-million-in-sales-expected-for-tetraphase-pharmaceuticals-inc-ttph-this-quarter.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.